6 results on '"Cohen-Harazi R"'
Search Results
2. Metabolic alterations and cellular responses to β-Hydroxybutyrate treatment in breast cancer cells.
- Author
-
Fulman-Levy H, Cohen-Harazi R, Levi B, Argaev-Frenkel L, Abramovich I, Gottlieb E, Hofmann S, Koman I, and Nesher E
- Abstract
Background: The ketogenic diet (KD), based on high fat (over 70% of daily calories), low carbohydrate, and adequate protein intake, has become popular due to its potential therapeutic benefits for several diseases including cancer. Under KD and starvation conditions, the lack of carbohydrates promotes the production of ketone bodies (KB) from fats by the liver as an alternative source of metabolic energy. KD and starvation may affect the metabolism in cancer cells, as well as tumor characteristics. The aim of this study is to evaluate the effect of KD conditions on a wide variety of aspects of breast cancer cells in vitro., Methods: Using two cancer and one non-cancer breast cell line, we evaluate the effect of β-hydroxybutyrate (βHb) treatment on cell growth, survival, proliferation, colony formation, and migration. We also assess the effect of KB on metabolic profile of the cells. Using RNAseq analysis, we elucidate the effect of βHb on the gene expression profile., Results: Significant effects were observed following treatment by βHb which include effects on viability, proliferation, and colony formation of MCF7 cells, and different effects on colony formation of MDA-MB-231 cells, with no such effects on non-cancer HB2 cells. We found no changes in glucose intake or lactate output following βHb treatment as measured by LC-MS, but an increase in reactive oxygen species (ROS) level was detected. RNAseq analysis demonstrated significant changes in genes involved in lipid metabolism, cancer, and oxidative phosphorylation., Conclusions: Based on our results, we conclude that differential response of cancer cell lines to βHb treatment, as alternative energy source or signal to alter lipid metabolism and oncogenicity, supports the need for a personalized approach to breast cancer patient treatment., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
3. Optimizing the average distance between a blue light photosensitizer and a harmonic nanoparticle for effective infrared photodynamic therapy.
- Author
-
Barbora A, Lyssenko S, Amar M, Nave V, Zivan V, Argaev Frenkel L, Nause A, Cohen-Harazi R, and Minnes R
- Subjects
- Photosensitizing Agents pharmacology, Photosensitizing Agents therapeutic use, Infrared Rays, Photochemotherapy methods, Nanoparticles, Curcumin
- Abstract
Photodynamic therapy can be significantly improved by techniques utilizing light windows of higher tissue penetration depths with optimally matched photoactive agents to provide deep interstitial treatment. Classical blue light photosensitizers were photodynamically activated using infrared light via coupled harmonic nanoparticles with optimized intermediary distances using spacers. Upon 800 nm pulsed laser irradiation perovskite nanoparticles with optimized coupling to either curcumin or protoporphyrin IX reduced the viability of MCF7 breast cancer cells by 73 percent and 64 percent, respectively, while exhibiting negligible dark toxicity. The findings pave the way for clinical adaptation of ease-of-synthesis photodynamically active preparations operable under deep tissue penetrating infrared lights using commonly available otherwise infrared inactive classical blue light photosensitizers., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Refael Minnes has patent NEAR-INFRARED PHOTODYNAMIC THERAPY USING SECOND HARMONIC GENERATION NANOPARTICLE AND VISIBLE LIGHT REACTIVE PHOTOSENSITIZER pending to Refael Minnes and Ayan Barbora]., (Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
4. Targeted Modulation of Interferon Response-Related Genes with IFN-Alpha/Lambda Inhibition.
- Author
-
Sur D, Leonova K, Levi B, Markowitz SI, Cohen-Harazi R, Gitlin I, Gurova K, Gudkov A, Pinhasov A, Koman I, and Nesher E
- Subjects
- Animals, Antiviral Agents pharmacology, Cytokines metabolism, Inflammation drug therapy, Inflammation genetics, Inflammation metabolism, Mice, Poly I-C pharmacology, Interferon-alpha genetics, Interferon-alpha pharmacology, Interferons genetics
- Abstract
Interferon (IFN) signaling resulting from external or internal inflammatory processes initiates the rapid release of cytokines and chemokines to target viral or bacterial invasion, as well as cancer and other diseases. Prolonged exposure to IFNs, or the overexpression of other cytokines, leads to immune exhaustion, enhancing inflammation and leading to the persistence of infection and promotion of disease. Hence, to control and stabilize an excessive immune response, approaches for the management of inflammation are required. The potential use of peptides as anti-inflammatory agents has been previously demonstrated. Our team discovered, and previously published, a 9-amino-acid cyclic peptide named ALOS4 which exhibits anti-cancer properties in vivo and in vitro. We suggested that the anti-cancer effect of ALOS4 arises from interaction with the immune system, possibly through the modulation of inflammatory processes. Here, we show that treatment with ALOS4 decreases basal cytokine levels in mice with chronic inflammation and prolongs the lifespan of mice with acute systemic inflammation induced by irradiation. We also show that pretreatment with ALOS4 reduces the expression of IFN alpha, IFN lambda, and selected interferon-response genes triggered by polyinosinic-polycytidylic acid (Poly I:C), a synthetic analog of viral double-stranded RNA, while upregulating the expression of other genes with antiviral activity. Hence, we conclude that ALOS4 does not prevent IFN signaling, but rather supports the antiviral response by upregulating the expression of interferon-response genes in an interferon-independent manner.
- Published
- 2022
- Full Text
- View/download PDF
5. Patient-derived tumor spheroid cultures as a promising tool to assist personalized therapeutic decisions in breast cancer.
- Author
-
Hofmann S, Cohen-Harazi R, Maizels Y, and Koman I
- Abstract
Background: Breast cancer is the most common cause of cancer related deaths in women. Treatment of breast cancer has many limitations including a lack of accurate biomarkers to predict success of chemotherapy and intrinsic resistance of a significant group of patients to the gold standard of therapy. Therefore, new tools are needed to provide doctors with guidance in choosing the most effective treatment plan for a particular patient and thus to increase the survival rate for breast cancer patients., Methods: Here, we present a successful method to grow in vitro spheroids from primary breast cancer tissue. Samples were received in accordance with relevant ethical guidelines and regulations. After tissue dissociation, in vitro spheroids were generated in a scaffold-free 96-well plate format. Spheroid composition was investigated by immunohistochemistry (IHC) of epithelial [pan cytokeratin (panCK)], stromal (vimentin) and breast cancer-specific markers (ER, PR, HER2, GATA). Growth and cell viability of the spheroids were assessed upon treatment with multiple anti-cancer compounds. Student's t -test and two-way ANOVA test were used to determine statistical significance., Results: We were able to successfully grow spheroids from 27 out of 31 samples from surgical resections of breast cancer tissue from previously untreated patients. Recapitulation of the histopathology of the tissue of origin was confirmed. Furthermore, a drug panel of standard first-line chemotherapy drugs used to treat breast cancer was applied to assess the viability of the patient-derived spheroids and revealed variation between samples in the response of the spheroids to different drug treatments., Conclusions: We investigated the feasibility and the utility of an in vitro , patient-derived spheroid model for breast cancer therapy, and we conclude that spheroids serve as a highly effective platform to explore cancer therapeutics and personalized treatment efficacy. These results have significant implications for the application of this model in clinical personalized medicine., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-21-1577/coif). The authors have no conflicts of interest to declare., (2022 Translational Cancer Research. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
6. Cytotoxicity of Exogenous Acetoacetate in Lithium Salt Form Is Mediated by Lithium and Not Acetoacetate.
- Author
-
Cohen-Harazi R, Hofmann S, Kogan V, Fulman-Levy H, Abaev K, Shovman O, Brider T, and Koman I
- Subjects
- Acetoacetates chemistry, Adenosine Triphosphate metabolism, Breast Neoplasms metabolism, Breast Neoplasms pathology, Cations, Monovalent chemistry, Cations, Monovalent pharmacology, Cell Growth Processes drug effects, Cell Line, Tumor, Humans, Lithium chemistry, Lithium Chloride chemistry, Lithium Chloride pharmacology, Lithium Compounds chemistry, MCF-7 Cells, Acetoacetates pharmacology, Breast Neoplasms drug therapy, Lithium pharmacology, Lithium Compounds pharmacology
- Abstract
Background/aim: The ketogenic diet has recently gained interest as potential adjuvant therapy for cancer. Many researchers have endeavored to support this claim in vitro. One common model utilizes treatment with exogenous acetoacetate in lithium salt form (LiAcAc). We aimed to determine whether the effects of treatment with LiAcAc on cell viability, as reported in the literature, accurately reflect the influence of acetoacetate., Materials and Methods: Breast cancer and normal cell lines were treated with acetoacetate, in lithium and sodium salt forms, and cell viability was assessed., Results: The effect of LiAcAc on cells was mediated by Li ions. Our results showed that the cytotoxic effects of LiAcAc treatment were significantly similar to those caused by LiCl, and also treatment with NaAcAc did not cause any significant cytotoxic effect., Conclusion: Treatment of cells with LiAcAc is not a convincing in vitro model for studying ketogenic diet. These findings are highly important for interpreting previously published results, and for designing new experiments to study the ketogenic diet in vitro., (Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.